Nanoencapsulation of a glucocorticoid improves barrier function and anti-inflammatory effect on monolayers of pulmonary epithelial cell lines.

2.50
Hdl Handle:
http://hdl.handle.net/10033/621014
Title:
Nanoencapsulation of a glucocorticoid improves barrier function and anti-inflammatory effect on monolayers of pulmonary epithelial cell lines.
Authors:
Rigo, Lucas A; Carvalho-Wodarz, Cristiane S; Pohlmann, Adriana R; Guterres, Silvia S; Schneider-Daum, Nicole; Lehr, Claus Michael ( 0000-0002-5864-8462 ) ; Beck, Ruy C R
Abstract:
The anti-inflammatory effect of polymeric deflazacort nanocapsules (NC-DFZ) was investigated, and possible improvement of epithelial barrier function using filter grown monolayers of A549 and Calu-3 using as models was assessed. NC prepared from poly(ε-caprolactone) (PCL) had a mean size around 200 nm, slightly negative zeta potential (∼ - 8 mV), and low polydispersity index (< 0.10). Encapsulation of DFZ had an efficiency of 85%. No cytotoxic effects were observed at particle concentration of 9.85 x 10(11) NC/ml, which was therefore chosen to evaluate the effect of NC-DFZ at 1% (w/v) of PCL and 0.5% (w/v) of DFZ on the epithelial barrier function of Calu-3 monolayers. Nanoencapsulated drug at 0.5% (w/v) increased transepithelial electrical resistance and decrease permeability of the paracellular marker sodium fluorescein, while non-encapsulated DFZ failed to improve these parameters. Moreover, NC-DFZ reduced the lipopolysaccharide (LPS) mediated secretion of the inflammatory marker IL-8. In vitro dissolution testing revealed controlled release of DFZ from nanocapsules, which may explain the improved effect of DFZ on the cells. These data suggest that nanoencapsulation of pulmonary delivered corticosteroids could be advantageous for the treatment of inflammatory conditions, such as asthma and chronic obstructive pulmonary diseases.
Affiliation:
Helmholtz-Institut für Pharmazeutische Forschung Saarland [HIPS], Universitätscampus E8.1, 66123 Saarbrücken, Germany.
Citation:
Nanoencapsulation of a glucocorticoid improves barrier function and anti-inflammatory effect on monolayers of pulmonary epithelial cell lines. 2017 Eur J Pharm Biopharm
Journal:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
Issue Date:
13-May-2017
URI:
http://hdl.handle.net/10033/621014
DOI:
10.1016/j.ejpb.2017.05.006
PubMed ID:
28512018
Type:
Article
Language:
en
ISSN:
1873-3441
Appears in Collections:
publications of the department drug delivery ([TC] DDEL)

Full metadata record

DC FieldValue Language
dc.contributor.authorRigo, Lucas Aen
dc.contributor.authorCarvalho-Wodarz, Cristiane Sen
dc.contributor.authorPohlmann, Adriana Ren
dc.contributor.authorGuterres, Silvia Sen
dc.contributor.authorSchneider-Daum, Nicoleen
dc.contributor.authorLehr, Claus Michaelen
dc.contributor.authorBeck, Ruy C Ren
dc.date.accessioned2017-07-19T10:54:57Z-
dc.date.available2017-07-19T10:54:57Z-
dc.date.issued2017-05-13-
dc.identifier.citationNanoencapsulation of a glucocorticoid improves barrier function and anti-inflammatory effect on monolayers of pulmonary epithelial cell lines. 2017 Eur J Pharm Biopharmen
dc.identifier.issn1873-3441-
dc.identifier.pmid28512018-
dc.identifier.doi10.1016/j.ejpb.2017.05.006-
dc.identifier.urihttp://hdl.handle.net/10033/621014-
dc.description.abstractThe anti-inflammatory effect of polymeric deflazacort nanocapsules (NC-DFZ) was investigated, and possible improvement of epithelial barrier function using filter grown monolayers of A549 and Calu-3 using as models was assessed. NC prepared from poly(ε-caprolactone) (PCL) had a mean size around 200 nm, slightly negative zeta potential (∼ - 8 mV), and low polydispersity index (< 0.10). Encapsulation of DFZ had an efficiency of 85%. No cytotoxic effects were observed at particle concentration of 9.85 x 10(11) NC/ml, which was therefore chosen to evaluate the effect of NC-DFZ at 1% (w/v) of PCL and 0.5% (w/v) of DFZ on the epithelial barrier function of Calu-3 monolayers. Nanoencapsulated drug at 0.5% (w/v) increased transepithelial electrical resistance and decrease permeability of the paracellular marker sodium fluorescein, while non-encapsulated DFZ failed to improve these parameters. Moreover, NC-DFZ reduced the lipopolysaccharide (LPS) mediated secretion of the inflammatory marker IL-8. In vitro dissolution testing revealed controlled release of DFZ from nanocapsules, which may explain the improved effect of DFZ on the cells. These data suggest that nanoencapsulation of pulmonary delivered corticosteroids could be advantageous for the treatment of inflammatory conditions, such as asthma and chronic obstructive pulmonary diseases.en
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleNanoencapsulation of a glucocorticoid improves barrier function and anti-inflammatory effect on monolayers of pulmonary epithelial cell lines.en
dc.typeArticleen
dc.contributor.departmentHelmholtz-Institut für Pharmazeutische Forschung Saarland [HIPS], Universitätscampus E8.1, 66123 Saarbrücken, Germany.en
dc.identifier.journalEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.Ven

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.